K
Kazuo Tsubota
Researcher at Keio University
Publications - 1421
Citations - 57308
Kazuo Tsubota is an academic researcher from Keio University. The author has contributed to research in topics: Cornea & Visual acuity. The author has an hindex of 105, co-authored 1379 publications receiving 48991 citations. Previous affiliations of Kazuo Tsubota include Chiba University & Showa University.
Papers
More filters
Journal ArticleDOI
TFOS DEWS II Definition and Classification Report
Jennifer P. Craig,Kelly K. Nichols,Esen K. Akpek,Barbara Caffery,Harminder S Dua,Choun Ki Joo,Zuguo Liu,J. Daniel Nelson,J. Daniel Nelson,Jason J. Nichols,Kazuo Tsubota,Fiona Stapleton +11 more
TL;DR: The new definition recognizes the multifactorial nature of dry eye as a disease where loss of homeostasis of the tear film is the central pathophysiological concept and central to the scheme is a positive diagnosis of DED with signs and symptoms, and this is directed towards management to restore homeostosis.
Journal ArticleDOI
The international workshop on meibomian gland dysfunction: Executive summary
Kelly K. Nichols,Gary N. Foulks,Anthony J. Bron,Ben J. Glasgow,Murat Dogru,Kazuo Tsubota,Michael A. Lemp,David A. Sullivan +7 more
TL;DR: This paper presents a poster presented at the first International Workshop on Meibomian Gland Dysfunction at the annual meeting of the Tear Film and Ocular Surface Society in Toronto, Canada.
Journal ArticleDOI
A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details
Hisanori Umehara,Kazuichi Okazaki,Yasufumi Masaki,Mitsuhiro Kawano,Motohisa Yamamoto,Takako Saeki,Shoko Matsui,Takayuki Sumida,Tsuneyo Mimori,Yoshiya Tanaka,Kazuo Tsubota,Tadashi Yoshino,Shigeyuki Kawa,Ritsuro Suzuki,Tsutomu Takegami,Naohisa Tomosugi,Nozomu Kurose,Yasuhito Ishigaki,Atsushi Azumi,Masaru Kojima,Shigeo Nakamura,Dai Inoue +21 more
TL;DR: Although IgG4RD forms a distinct, clinically independent disease category and is attracting strong attention as a new clinical entity, many questions and problems still remain to be elucidated, including its pathogenesis, the establishment of diagnostic criteria, and the role of IgG 4.
Journal ArticleDOI
Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders
Yasufumi Masaki,Lingli Dong,Lingli Dong,Nozomu Kurose,Kazuko Kitagawa,Yuko Morikawa,Motohisa Yamamoto,Hiroki Takahashi,Yasuhisa Shinomura,Kohzoh Imai,Takako Saeki,Atsushi Azumi,Shinji Nakada,Eiji Sugiyama,Shoko Matsui,Tomoki Origuchi,Susumu Nishiyama,Isao Nishimori,Takayuki Nojima,Kazunori Yamada,Mitsuhiro Kawano,Yoh Zen,Masahiko Kaneko,Kana Miyazaki,Kazuo Tsubota,Katsumi Eguchi,Kouichi Tomoda,Toshioki Sawaki,Takafumi Kawanami,Masao Tanaka,Toshihiro Fukushima,Susumu Sugai,Hisanori Umehara +32 more
TL;DR: There are considerable clinical and pathological differences between IgG4+MOLPS and SS, and based on the clinical features and good response to glucocorticoids, a new clinical entity is proposed: IgG 4+MolPS.
Journal ArticleDOI
The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction.
Gerd Geerling,Joseph Tauber,Christophe Baudouin,Eiki Goto,Yukihiro Matsumoto,Terrence P. O'Brien,Maurizio Rolando,Kazuo Tsubota,Kelly K. Nichols +8 more
TL;DR: The goals of the subcommittee were to review the current practice and published evidence of medical and surgical treatment options for meibomian gland dysfunction and to identify areas with conflicting, or lack of, evidence, observations, concepts, or even mechanisms where further research is required.